Skip to main content
  • Consumer Website
  • Contact Us
 
 
Bayer logo
Bayer logo
Logo
Logo
 
 

ATTENTION

The information on this page is intended for healthcare professionals in the.
United States and is not intended for the general public.

I AM A HEALTHCARE PROFESSIONAL

I AM NOT A HEALTHCARE PROFESSIONAL

Home
  • Product
  • Efficacy
  • Pediatric
  • PRN Dosing
  • Safety & Tolerability
  • FAQ
  • Resources
  • Sign Up for Coupons and More
Bayer Cross Logo
  1. Home
  2. Safety & Tolerability
Spectrum pattern
Image
12 years yellow icon

With more than 12 years in clinical use as a prescription product, Astepro has a well-established safety profile.1

  • In clinical trials, drowsiness was observed in less than 4% of patients taking Astepro2,3
LEARN MORE
steroid free yellow icon

Astepro is a steroid-free allergy relief option4 for patients who want to avoid ongoing steroid use.

  • Astepro does not have a warning regarding pediatric growth suppression in its Drug Facts Label4
  • Astepro® Allergy is the same strength as prescription Astepro® (azelastine HCI) 0.15% Nasal Spray, 205.5 mcg (Rx approval in 2009), and is the maximum strength of azelastine HCI available as a prescription or over the counter.2,4,5
LEARN MORE
tongue with taste buds yellow icon

Astepro® Allergy also has the same improved taste profile as prescription Astepro®2,4

  • In clinical trials, 94% of patients receiving Astepro® reported no bitter taste2,6
  • It is different than both Astelin® (azelastine HCI) Nasal Spray 137 mcg (Rx approval in 1996), and Astepro (azelastine HCI) 0.10% Nasal Spray 137 mcg (Rx approval in 2008).2,7 It has a 50% higher concentration of azelastine HCI than prescription Astelin2,4,7 and also has the same improved taste profile as prescription Astepro.2,4,6
  • Astepro Allergy includes the artificial sweetener ingredients sucralose and sorbitol.4,6
LEARN MORE

References:
1. US Food and Drug Administration. NDA 22-371. Drug Approval package for Astepro® Nasal Spray. August 31, 2009. 2. Astepro® Prescribing information. Meda Pharmaceuticals Inc; 2018. 3. Data on file. Bayer. MP436 CSR Safety and tolerability. 4. NDA 213872. 5. US Department of Health and Human Services. Pediatric Postmarketing Pharmacovigilance and Drug Utilization Review. November 3, 2016. Accessed October 28, 2021. https://www.fda gov/media/100100/download 6. van Bavel J, Howland WC, Amar NJ, Wheeler W, Sacks H. Efficacy and safety of azelastine 0.15% nasal spray administered once daily in subjects with seasonal allergic rhinitis. Allergy Asthma Proc. 2009;30(5):512-518. doi:10.2500/aap.2009.30.3284. 7. Astelin. Prescribing information. Meda Pharmaceuticals Inc; 2014.

Spectrum pattern

SIGN UP TO RECEIVE UPDATES ABOUT ASTEPRO® ALLERGY

 
Get product updates, coupons and free patient samples when they become available.

Astepro Logo
  • PRODUCT
  • EFFICACY
  • PEDIATRIC
  • PRN DOSING
  • SAFETY & TOLERABILITY
  • FAQ
  • RESOURCES
  • SIGN UP FOR COUPONS AND MORE
  • SITE MAP

©2023. Bayer and the Bayer Cross are registered trademarks of Bayer. Astepro is a Viatris Company trademark. Used under license. All third party trademarks used herein are registered trademarks of their respective owners.

USE AS DIRECTED

  • Bayer Global
  • Bayer US
  • Bayer Consumer Health
  • Conditions of Use
  • Privacy Statement
  • Imprint
  • California Transparency in Supply Chains
  • Satisfaction Guarantee
  • AdChoices
  • Do not sell or share my Personal Data
  • Accessibility

Level Access website accessibility icon